Dose Response Effects of Marine Omega-3 Fatty Acids on Inflammation
NCT ID: NCT01078909
Last Updated: 2023-08-21
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
125 participants
INTERVENTIONAL
2011-10-31
2014-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of a Prescription Omega-3 Fatty Acid Concentrate on Induced Inflammation
NCT01813110
Investigating the Effect of 4-week Omega-3 Polyunsaturated Fatty Acid Supplementation on Inflammation
NCT03210805
Effects of Omega-3 Fatty Acids on Markers of Inflammation
NCT01129050
Eicosapentaenoic Acid (EPA)and Docosahexaenoic Acid Study
NCT01400490
Effects of Omega-3 Fatty Acids in Ambient Air Pollution Exposure in Healthy Adults
NCT02921048
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Some studies have demonstrated a dose-response relationship between dietary eicosapentaenoic acid and docosahexaenoic acid (EPA + DHA) and increased membrane (phospholipid) EPA and DHA. Red blood cell (RBC) EPA + DHA content has been proposed as a potential, modifiable marker for coronary heart disease (CHD) risk. It is well established that these fatty acids are precursors of series-3 prostanoids, thromboxanes, 5-series leukotrienes, and novel lipid mediators such as resolvins and protectins that have anti-inflammatory effects. We hypothesize that nutritionally-relevant intakes of omega-3 fatty acids are able to blunt the usual response to an inflammatory stimulus. We propose to test this hypothesis using both in vivo (i.v. endotoxin challenge) and ex vivo (endotoxin-stimulated monocytes) models in a 6-month, dose-response study with marine-derived omega-3 fatty acid supplements in healthy volunteers.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
300mg Fish Oil (EPA + DHA) Supplement
Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA)
Comparison of 4 doses of EPA+DHA on in vivo and ex vivo (monocytes) response to an inflammatory stimulus (endotoxin) following a 6 month supplementation period
600mg Fish Oil (EPA+DHA) Supplement
Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA)
Comparison of 4 doses of EPA+DHA on in vivo and ex vivo (monocytes) response to an inflammatory stimulus (endotoxin) following a 6 month supplementation period
900mg Fish Oil (EPA + DHA) Supplement
Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA)
Comparison of 4 doses of EPA+DHA on in vivo and ex vivo (monocytes) response to an inflammatory stimulus (endotoxin) following a 6 month supplementation period
1800mg Fish Oil (EPA + DHA) Supplement
Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA)
Comparison of 4 doses of EPA+DHA on in vivo and ex vivo (monocytes) response to an inflammatory stimulus (endotoxin) following a 6 month supplementation period
Placebo
Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA)
Comparison of 4 doses of EPA+DHA on in vivo and ex vivo (monocytes) response to an inflammatory stimulus (endotoxin) following a 6 month supplementation period
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA)
Comparison of 4 doses of EPA+DHA on in vivo and ex vivo (monocytes) response to an inflammatory stimulus (endotoxin) following a 6 month supplementation period
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI \>19.9 and \<30.0
* Able to give written informed consent and willing to comply with all study- related procedures.
Exclusion Criteria
* Renal Insufficiency
* Chronic anti-inflammatory use
* Systolic blood pressure \< 90
* Individuals currently using tobacco products or have done so in the previous 30 days
* Individuals taking Omega-3 fatty acid supplements or their usual intake of fish is greater than 3-4 servings per month.
20 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
United States Department of Agriculture (USDA)
FED
Penn State University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gordon L Jensen, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Penn State University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Penn State University
University Park, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Flock MR, Skulas-Ray AC, Harris WS, Etherton TD, Fleming JA, Kris-Etherton PM. Determinants of erythrocyte omega-3 fatty acid content in response to fish oil supplementation: a dose-response randomized controlled trial. J Am Heart Assoc. 2013 Nov 19;2(6):e000513. doi: 10.1161/JAHA.113.000513.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PKE LPS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.